S-1: Shuttle Pharmaceuticals Seeks to Resell Shares Following Convertible Note and Warrant Issuance

Shuttle Pharmaceuticals is registering for resale 1,464,268 shares of common stock underlying convertible notes and 329,461 shares of common stock issuable upon exercise of warrants, all issued in a recent private placement.

Summary

• Shuttle Pharmaceuticals is registering for resale 1,464,268 shares of common stock underlying convertible notes and 329,461 shares of common stock issuable upon exercise of warrants.
• These securities were issued in a private placement in October 2024.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, except for potential proceeds from the exercise of warrants.
• The company may receive up to approximately $469,214 from the exercise of all warrants, assuming they are exercised in full for a weighted-average cash price of $1.42 per share.
• The company's common stock trades on the Nasdaq Capital Market under the symbol SHPH.
• As of January 13, 2025, the last reported sale price of the company's common stock was $0.8999 per share.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focusing on the details of the securities being registered for resale. While it highlights the potential for additional funding through warrant exercises, it also acknowledges the risks associated with the company's financial position and reliance on future capital raises.

Positives

• The company has the potential to receive additional capital if the warrants are exercised for cash.
• The company has completed a private placement of convertible notes and warrants.

Negatives

• The company will not receive any proceeds from the sale of the shares by the selling stockholders.
• The company is dependent on the selling stockholders exercising their warrants to receive additional capital.

Risks

• The company's stock price is volatile and an investment in the company's common stock involves significant risks.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.
• The company's ability to continue as a going concern is dependent upon its ability to successfully raise additional equity or debt financing to fund its operations.
• The company's success is primarily dependent on achieving the development, regulatory approval and commercialization of its product candidates, both of which are in the early stages of development.
• The company has no product revenue, has incurred significant losses since inception, may never become profitable and may incur substantial and increasing net losses for the foreseeable future.

Future Outlook

The company intends to use the net proceeds from the exercise of warrants, if any, to fund IND-enabling and Phase I and II clinical trials of product candidates.

Industry Context

The document relates to a capital raise by a clinical-stage pharmaceutical company, which is common in the biotechnology industry. The company is seeking to fund its ongoing operations and clinical trials.

Comparison to Industry Standards

• The company's reliance on private placements and potential warrant exercises for funding is typical for early-stage biotech companies.
• The company's focus on radiation sensitizers and immune response regulating drugs is a growing area of interest in the oncology field.
• The company's status as an emerging growth company and its election to comply with reduced reporting requirements is common for companies of its size and stage of development.
• The company's need for additional capital to fund its operations and clinical trials is a common challenge for early-stage biotech companies.
• The company's reliance on third-party manufacturers and CROs is a common practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• Shareholders may experience volatility in the stock price.
• The company's ability to fund its operations and clinical trials is dependent on its ability to raise additional capital.

Next Steps

• The company intends to use the net proceeds from the exercise of warrants, if any, to fund IND-enabling and Phase I and II clinical trials of product candidates.

Key Dates

Keywords

common stock, convertible notes, warrants, resale, private placement, Nasdaq, emerging growth company, pharmaceuticals, capital raise